|Day Low/High||49.21 / 49.73|
|52 Wk Low/High||42.48 / 63.69|
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Bristol-Myers Squibb Company (NYSE: BMY) today announced long-term pooled efficacy and safety results from the Phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer (NSCLC).
Opdivo failed to show any measurable improvement in patients with a particularly aggressive and rare form of brain cancer compared with patients treated with the current standard of care.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard of care alone did not...
Bristol-Myers Squibb Company (NYSE:BMY) employee Dana Vaughns will celebrate his 10-year anniversary of surviving bone cancer by taking on the physical challenge of his life.
Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple...
SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced it has entered into a research...
Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Jim Cramer weighs in on the U.S.-China trade war and Amgen.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
We will sell out of one of the most expensive stocks in the portfolio (Shopify) with no yield and redeploy that capital into one of the cheapest in the portfolio with a solid yield (Viacom).
Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.
Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under which Amgen would acquire...
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World
Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.
Jim Cramer says if you want to see the U.S. economy's strength, look to Home Depot, where the consumer's confidence and influence remains healthy.
On a brutal day in an increasingly shaky market, Jim Cramer looks for companies that can meet the the challenges of China, the Fed, or a slowdown.
The Russell 2000, the Transports and the Bank Index haven’t gone anywhere for around nine months -- until this changes for the better, it’s unlikely the bulls can expect any sort of runaway train on the upside.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
- Facility will support gene therapy production and continued development of pipeline of investigational medicines -
These stocks and sectors are safe havens, and may even be opportunities.
The most recent short interest data was recently released for the 04/15/2019 settlement date, and Bristol-Myers Squibb Co. is the #186 most shorted of the S&P 500 components, based on 4.20 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.